Improvement of schizophrenic symptoms and changes in plasma HVA concentrations, plasma anti-D2 and anti-5-HT2 receptor activities with clozapine

Kazuo Yamada; Shigenobu Kanba; Zu Cheng Wang; Eiji Suzuki; Yi Yu Fang; He Gin Yan; Masashi Nibuya; Gohei Yagi; Masahiro Asai

doi:10.1111/j.1440-1819.1996.tb00566.x

Improvement of schizophrenic symptoms and changes in plasma HVA concentrations, plasma anti-D₂ and anti-5-HT₂ receptor activities with clozapine

Kazuo Yamada, Shigenobu Kanba, Zu Cheng Wang, Eiji Suzuki, Yi Yu Fang, He Gin Yan, Masashi Nibuya, Gohei Yagi, Masahiro Asai

Internal Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

In order to investigate the biological mechanisms underlying the clinical efficacy of clozapine, 200 mg/day of clozapine was added to the drug regimens of 19 patients with chronic, anti-psychotic-resistant schizophrenia, and the plasma homovanillic acid (HVA), clozapine concentrations, anti- dopamine D₂ and anti-serotonin 5-HT₂ receptor activities were measured. After 28 days, six patients showed an improvement of more than 20% over baseline Brief Psychiatric Rating Scale (BPRS) scores. Mean plasma HVA concentrations and anti-D₂ receptor activities did not change significantly in the entire group or in the six patients showing improvement. However, anti-5-HT₂ receptor activities increased significantly in all 19 patients. Changes in BPRS scores did not correlate significantly with changes in plasma HVA or with changes in clozapine concentrations, or with anti-D₂ and anti- 5-HT₂ receptor activities.

Original language	English
Pages (from-to)	291-294
Number of pages	4
Journal	Psychiatry and clinical neurosciences
Volume	50
Issue number	5
DOIs	https://doi.org/10.1111/j.1440-1819.1996.tb00566.x
Publication status	Published - Oct 1996

All Science Journal Classification (ASJC) codes

Neuroscience(all)
Neurology
Clinical Neurology
Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1440-1819.1996.tb00566.x

Cite this

@article{f12119ba033447a787faa98c215907e1,

title = "Improvement of schizophrenic symptoms and changes in plasma HVA concentrations, plasma anti-D2 and anti-5-HT2 receptor activities with clozapine",

abstract = "In order to investigate the biological mechanisms underlying the clinical efficacy of clozapine, 200 mg/day of clozapine was added to the drug regimens of 19 patients with chronic, anti-psychotic-resistant schizophrenia, and the plasma homovanillic acid (HVA), clozapine concentrations, anti- dopamine D2 and anti-serotonin 5-HT2 receptor activities were measured. After 28 days, six patients showed an improvement of more than 20% over baseline Brief Psychiatric Rating Scale (BPRS) scores. Mean plasma HVA concentrations and anti-D2 receptor activities did not change significantly in the entire group or in the six patients showing improvement. However, anti-5-HT2 receptor activities increased significantly in all 19 patients. Changes in BPRS scores did not correlate significantly with changes in plasma HVA or with changes in clozapine concentrations, or with anti-D2 and anti- 5-HT2 receptor activities.",

author = "Kazuo Yamada and Shigenobu Kanba and Wang, {Zu Cheng} and Eiji Suzuki and Fang, {Yi Yu} and Yan, {He Gin} and Masashi Nibuya and Gohei Yagi and Masahiro Asai",

year = "1996",

month = oct,

doi = "10.1111/j.1440-1819.1996.tb00566.x",

language = "English",

volume = "50",

pages = "291--294",

journal = "Psychiatry and Clinical Neurosciences",

issn = "1323-1316",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Improvement of schizophrenic symptoms and changes in plasma HVA concentrations, plasma anti-D2 and anti-5-HT2 receptor activities with clozapine

AU - Yamada, Kazuo

AU - Kanba, Shigenobu

AU - Wang, Zu Cheng

AU - Suzuki, Eiji

AU - Fang, Yi Yu

AU - Yan, He Gin

AU - Nibuya, Masashi

AU - Yagi, Gohei

AU - Asai, Masahiro

PY - 1996/10

Y1 - 1996/10

N2 - In order to investigate the biological mechanisms underlying the clinical efficacy of clozapine, 200 mg/day of clozapine was added to the drug regimens of 19 patients with chronic, anti-psychotic-resistant schizophrenia, and the plasma homovanillic acid (HVA), clozapine concentrations, anti- dopamine D2 and anti-serotonin 5-HT2 receptor activities were measured. After 28 days, six patients showed an improvement of more than 20% over baseline Brief Psychiatric Rating Scale (BPRS) scores. Mean plasma HVA concentrations and anti-D2 receptor activities did not change significantly in the entire group or in the six patients showing improvement. However, anti-5-HT2 receptor activities increased significantly in all 19 patients. Changes in BPRS scores did not correlate significantly with changes in plasma HVA or with changes in clozapine concentrations, or with anti-D2 and anti- 5-HT2 receptor activities.

AB - In order to investigate the biological mechanisms underlying the clinical efficacy of clozapine, 200 mg/day of clozapine was added to the drug regimens of 19 patients with chronic, anti-psychotic-resistant schizophrenia, and the plasma homovanillic acid (HVA), clozapine concentrations, anti- dopamine D2 and anti-serotonin 5-HT2 receptor activities were measured. After 28 days, six patients showed an improvement of more than 20% over baseline Brief Psychiatric Rating Scale (BPRS) scores. Mean plasma HVA concentrations and anti-D2 receptor activities did not change significantly in the entire group or in the six patients showing improvement. However, anti-5-HT2 receptor activities increased significantly in all 19 patients. Changes in BPRS scores did not correlate significantly with changes in plasma HVA or with changes in clozapine concentrations, or with anti-D2 and anti- 5-HT2 receptor activities.

UR - http://www.scopus.com/inward/record.url?scp=0029782463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029782463&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1819.1996.tb00566.x

DO - 10.1111/j.1440-1819.1996.tb00566.x

M3 - Article

C2 - 9201793

AN - SCOPUS:0029782463

SN - 1323-1316

VL - 50

SP - 291

EP - 294

JO - Psychiatry and Clinical Neurosciences

JF - Psychiatry and Clinical Neurosciences

IS - 5

ER -